Translating the results of clinical trials into improved outcomes for these individuals requires an understanding of how best to manage the adverse effects of these agents. Despite the enthusiasm, however, the reality is that many patients are still frail and remain at risk for treatment-related complications. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than 7+3 has been transformative. What are the implications versus the standard of care? How do outcomes and costs impact pricing potential? How can affirmative data (e.g.The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. How will the product influence the clinical pathway? Are there data that can be leveraged at launch to influence reimbursement and market access? What outcomes matter and differentiate it? Can the system afford it? Key FactorsĬan I afford it? Is it easy for me to adopt it? Below are some of the key questions that you need asked and that we can help answer. To fully understand your product’s value story, you need to take into account many different factors and perspectives. Your Value Story: Key Questions to Answer For face-to-face meetings, we can conduct interactive workshops to maximize engagement between attendees and ensure active learning. We can support you with this by presenting a range of value demonstration materials, including mock-payer training at roll-out meetings, either face-to-face or via WebEx. Training & WorkshopsĪs you approach product launch, you will need to communicate all aspects of a product’s value to your affiliate teams. They can be developed in collaboration with your affiliates and incorporate payer research to ensure both the questions and answers are relevant and impactful. Objection handlers are for reactive use when your teams are challenged by payers and need to respond quickly, but accurately, with a globally approved answer. Typical audiences for these slide sets include stakeholders in non-HTA markets and regional and local payers. To help you communicate with audiences who may not require the level of detail contained in the GVD, we can develop slide sets to present your information in a clear and concise format. Value of the product (clinical, humanistic, economic).Information is presented so that all users are able to access the sections they need and affiliates can apply the value story to their local markets. GVDs present evidence-based messages that demonstrate what your new product brings to the market and how it will be positioned relative to other products. To help communicate your product’s value, we can provide a wide range of deliverables including GVDs, market access toolkits, slide sets, objection handlers, and onsite or virtual training and workshops. Let us help develop your global value dossiers (GVDs) and other high-impact communication tools to ensure your research findings and value messages can be adopted by the relevant audiences. Your messages need to be flexible, tailored to each of your audiences, and clearly articulated.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |